Fe-based cyclically catalyzing double free radical nanogenerator for tumor-targeted chemodynamic therapy.

J Mater Chem B

Hubei Collaborative Innovation Center for Advanced Organic Chemical Materials, Ministry of Education Key Laboratory for the Synthesis and Application of Organic Functional Molecules, College of Chemistry and Chemical Engineering, Hubei University, Wuhan 430062, China.

Published: May 2024

The prosperity of chemodynamic therapy provides a new strategy for tumor treatment. However, the lack of reactive oxygen species and the specific reductive tumor microenvironment have limited the further development of chemodynamic therapy. Herein, we reported a Fe-based cyclically catalyzing double free radical system for tumor therapy by catalyzing exogenous potassium persulfate (KSO) and endogenous hydrogen peroxide (HO). Sufficient amounts of Fe and SO were delivered to tumor sites tumor-targeted hyaluronic acid (HA) encapsulated mesoporous silica nanoparticles (MSNs) and released under the dual stimulation of acid and hyaluronidase (HAase) in the tumor microenvironment. Fe was reduced to Fe by the reducing agents of loaded tannic acid (TA) and intracellular glutathione (GSH), and Fe was subsequently reacted with SO and endogenous HO to produce two types of ROS (˙OH and SO˙), showing an excellent anti-tumor effect. This process not only supplied Fe for the catalysis of active substances, but also reduced the concentration of reduced substances in cells, which was conducive to the existence of free radicals for the efficient killing of tumor cells. Therefore, this iron-based catalysis of exogenous and exogenous active substances to realize a dual-radical oncotherapy nanosystem would provide a new perspective for chemodynamic therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1039/d3tb02763eDOI Listing

Publication Analysis

Top Keywords

chemodynamic therapy
16
fe-based cyclically
8
cyclically catalyzing
8
catalyzing double
8
double free
8
free radical
8
tumor microenvironment
8
active substances
8
tumor
6
therapy
5

Similar Publications

Cuproptosis is a newly discovered mode of cell death, which is caused by excess copper and results in cell death via the mitochondrial pathway. However, the complex tumor microenvironment (TME) is characterized by many factors, including high levels of glutathione and lack O, limit the application of traditional cuproptosis agents in antitumor therapy. Herein, we report a hyaluronic acid modified copper-manganese composite nanomedicine (CMCNs@HA) to remodel the TME and facilitate efficient cuproptosis in tumor.

View Article and Find Full Text PDF

A Multifunctional MIL-101-NH(Fe) Nanoplatform for Synergistic Melanoma Therapy.

Int J Nanomedicine

January 2025

Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People's Republic of China.

Background: Melanoma is an aggressive form of skin cancer, and single-modality treatments often fail to prevent tumor recurrence and metastasis. Combination therapy has emerged as an effective approach to improve treatment outcomes.

Methods: In this study, we developed a multifunctional nanoplatform, MIL@DOX@ICG, utilizing MIL-101-NH(Fe) as a carrier to co-deliver the chemotherapeutic agent doxorubicin (DOX) and the photosensitizer indocyanine green (ICG).

View Article and Find Full Text PDF

Tailored biomimetic nanoreactor improves glioma chemodynamic treatment via triple glutathione depletion and prompt acidity elevation.

Mater Today Bio

February 2025

Department of Neurosurgery, Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong University, Nantong, 226001, China.

Chemodynamic therapy (CDT) is an emerging antitumor strategy utilizing iron-initiated Fenton reaction to destroy tumor cells by converting endogenous HO into highly toxic hydroxyl radical (OH). However, the intratumoral overexpressed glutathione (GSH) and deficient acid greatly reduce CDT efficacy because of OH scavenging and decreased OH production efficiency. Even worse, the various physiological barriers, especially in glioma, further put the brakes on the targeted delivery of Fenton agents.

View Article and Find Full Text PDF

Carbon-supported Fe single atom nanozymes with long-lasting ROS generation and high NIR photothermal performance for synergistic cancer therapy.

J Colloid Interface Sci

April 2025

High Magnetic Field Laboratory, Hefei Institutes of Physical Science, Chinese Academy of Science, Hefei, Anhui 230031, PR China; University of Science and Technology of China, Hefei, Anhui 230026, PR China. Electronic address:

Synergistic therapy combining photothermal therapy (PTT) and chemodynamic therapy (CDT) has proven to be a highly effective strategy for cancer treatment. However, PTT heavily relies on the accumulation of therapeutic agents at the tumor site. The peroxidase (POD) activity of common catalysts can be rapidly exhausted during the accumulation process, prior to laser intervention, thereby diminishing the synergistic enhancement effect of the combined therapy.

View Article and Find Full Text PDF

Hyaluronic acid modified metal-organic frameworks loading cisplatin achieve combined chemodynamic therapy and chemotherapy for lung cancer.

Int J Biol Macromol

January 2025

Department of Oncology, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, PR China; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan 646000, PR China. Electronic address:

As one of the most commonly used chemotherapeutic agents in clinical practice, cisplatin is unable to selectively accumulate in tumor tissue due to its lack of targeting ability, leading to increased systemic toxicities. Additionally, the effectiveness of monotherapy is greatly limited. Therefore, the development of new cisplatin-based drug delivery systems is essential to improve the effectiveness of tumor treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!